Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 18, 2026American Journal of Hematology

Zanubrutinib in AL Amyloidosis Associated With Waldenström Macroglobulinemia and Other B‐Cell Non‐Hodgkin Lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

WVWouter VerhaarAmsterdam University Medical CentersFWFlores WeverlingUtrecht UniversityJKJahanzaib KhwajaUniversity College Hospital

Discussion

Loading...

Member takes

Implication

This retrospective study evaluates zanubrutinib's efficacy and safety in treating AL amyloidosis associated with B-cell lymphomas, indicating potential improvements over traditional therapies.

Key Points

  • Evaluate the clinical outcomes and tolerability of zanubrutinib in patients with AL amyloidosis associated with Waldenström macroglobulinemia (WM) or other B-cell non-Hodgkin lymphoma (B-NHL).
  • Conducted a multinational retrospective study across 11 centers including patient data on treatment responses and safety.
  • Analyzed hematologic and organ responses using established consensus criteria for AL amyloidosis.
  • Collected data from patients who received at least one dose of zanubrutinib between November 2020 and December 2024.
  • Out of 19 evaluable patients, an overall hematologic response rate of 42% was observed.
  • 4 of the responding patients achieved a very good partial response (VGPR).
  • The median overall survival (OS) at 12 months was 90%, although cardiac adverse events remained a concern.

Cite This Study

Verhaar et al. (2026) studied this question.

synapsesocial.com/papers/69ba42cf4e9516ffd37a3571https://doi.org/10.1002/ajh.70267
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase2019 · 364 citations
  2. 2Ibrutinib in Previously Treated Waldenström’s Macroglobulinemia2015 · 945 citations
  3. 3AL amyloidosis associated with IgM paraproteinemia: clinical profile and treatment outcome2008 · 85 citations
  4. 4Response assessment in W aldenström macroglobulinaemia: update from the VI th I nternational W orkshop2012 · 280 citations
  5. 5Indolent Lymphoma: High CR and VGPR Rate with Fixed Duration Bendamustine, Rituximab and Acalabrutinib in Waldenstroms Macroglobulinaemia (BRAWM)2023 · 4 citations